GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...
Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies
Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First
Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...
Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture...
Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment
US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...
LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline
LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...
Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device
Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...
Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion
Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...
China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets
The Ministry of Industry and Information Technology (MIIT) has released a report on the first...
China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results
The National Health Commission (NHC) of China has released a notice detailing the results of...
EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi
Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...
Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement
Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment...
Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...
AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...
3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...
CStone Pharmaceuticals’ Sugemalimab Wins EU Nod as First-Line NSCLC Treatment
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has received marketing approval...
Alphamab’s KN057 Earns FDA Orphan Drug Designation for Hemophilia B Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has received another orphan drug...